Commvault Systems Inc vs Mesoblast Limited — how do they compare? Commvault Systems Inc trades at $151.43 (market cap $6.25B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Commvault Systems Inc is far larger — about 3.6× Mesoblast Limited's market cap, and Commvault Systems Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Mesoblast Limited for 14 Days on average.
| CVLT | MESO | |
|---|---|---|
Market Cap | $6.25B | $1.75B |
Volume | 632,727 | 239,027 |
Sector | Technology | Health |
52-Week High | $176.52 | $20.96 |
52-Week Low | $75.18 | $13.19 |
Typical Hold Time | 17 Days | 14 Days |
Enterprise Value | $6.24B | $1.83B |
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $150.28, down 3.03% on the day, but maintains a bullish technical outlook with strong institutional support. The company shows robust earnings momentum with three consecutive quarterly beats and impressive profitability metrics including 81.09% gross margins and 32.77% ROE. Recent business developments include achieving AWS Data Competency and expanding FedRAMP High authorized services, positioning the company for continued growth in the cybersecurity resilience market.
CVLT presents a compelling growth story with strong fundamentals and positive analyst sentiment, though elevated valuation ratios (P/E 96.73, P/B 120.15) suggest premium pricing. The primary investment opportunity lies in the company's leadership in AI-era resilience solutions, while risks include valuation sensitivity and competitive pressures in the enterprise software space. Wall Street maintains a bullish stance with 54.55% buy ratings and a $156.55 consensus price target.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Trailing returns across standard periods
Latest headlines on both assets
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →